INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products Administration (NMPA) has approved its second-generation pan-TRK inhibitor, Zorletinib (ICP-723), for treating solid tumors in adults and adolescents aged 12 and above with NTRK fusion genes. Zorletinib has been included in NMPA's "Starlight Project," a pilot initiative to encourage pediatric oncology drug development. The company expects to soon submit a New Drug Application (NDA) for Zorletinib's use in pediatric patients aged 2 to 12. NTRK fusion genes are present in over 26 types of solid tumors, with an estimated 6,500 new cases annually in China. These patients often face short survival, rapid disease progression, and high disability rates. Due to low adoption of next-generation sequencing (NGS)—the gold standard for detection—diagnosis delays persist, leaving unmet clinical needs.